Maximilien Fournier Sourdille

NH TherAguix is a biotech company registered at RCS Grenoble and based 19, Chemin des prés, 38240 Meylan

Therapixel is a leading french software company specialized in artificial intelligence for medical imaging. Our aim is to develop a digital radiologist achieving the performance of best experts. Our AI is dedicated to breast cancer screening. That algorithm won the Digital Mammography DREAM Challenge, the largest Artificial Intelligence challenge ever organized. In its early years, Therapixel developed images visualization software for surgeons to make image access easier and faster from patient consultation to the operating room thanks to gesture control and intuitive user interfaces.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

EYE TECH CARE, based in Lyon, was founded in 2008 by experts in the field of therapeutic ultrasound. The company develops and markets medical devices for the non invasive treatment of eye diseases. Glaucoma and ocular hypertension affect some 12O million people around the world, but are diagnosed in only about 30% of cases. It is the second cause of blindness, according to WHO (World Health Organization). With the support of renowned scientific and financial partners, EYE TECH CARE has developed the EyeOP1, an unique therapeutic device. Its teams have designed the only medical procedure that currently addresses all patients with uncontrolled glaucoma, irrespective of their prior treatment history.

We are a clinical stage biopharmaceutical company developing developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases. We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and auto-immune diseases: - OncoMimics™: highly effective, off-the-shelf therapeutic vaccines against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin B-cell lymphomas. - EndoMimics™: a pipeline of next generation bioactives acting like human hormones or cytokines for the treatment of immune diseases. EB1010, the lead candidate, is a potent local inducer of IL-10 designed to provide improved therapeutic outcomes for patients with IBD. In addition, Enterome’s clinical candidate sibofimloc (also referred to as TAK-018) is advancing through a Phase 2 clinical trial in post-operative Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.

Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications. Exploiting the full potential of our proprietary Themaxyn® platform we are able to identify and rapidly advance vaccine candidates at various stages of development. Based on a well-proven base technology, the Themaxyn® platform offers both, an excellent safety profile and a validated manufacturing process. Themis Bioscience was founded in 2009 by a group of internationally renowned vaccine and biotech executives in Vienna, Austria. In 2014 Themis successfully completed a phase I clinical trial with our Chikungunya vaccine in Austria. Themis continues to head the race for preventing emerging infectious diseases and started a phase II clinical trial with our Chikungunya vaccine in 2016 and a phase I clinical trial with our Zika vaccine in 2017.

Gecko Biomedical is a fast-paced medical device company, dedicated to the development of innovative tissue reconstruction solutions. We are leveraging our technology platforms to develop novel solutions to disrupt the field of surgery and positively impact the life of patients.

The L.E.N. MEDICAL group is acting for constantly ameliorating medical skills of med specialists. We are based in France and covering widely european congress. Our activities : Congress organisation, spcialized press, digital medias, specialized publishing

Centres de Médecine Nucléaire CMN 4 (bientôt 5) sites en Ile-de-France : Champigny-sur-Marne - Jossigny - Meaux - Melun - Ouverture très prochaine du 5e site en Mai 2023 à Paris Scintigraphie et TEP/TDM (PET/CT, Petscan) 12 médecins et 50 collaborateurs 8 équipements gamma-caméras (dont 4 hybrides couplés TDM) 5 équipements TEP/TDM Depuis 1994, nos Centres de Médecine Nucléaire accueillent vos patients pour la réalisation de tous types d’examens Scintigraphies et TEP/TDM sur nos sites, du lundi au vendredi, de 8h à 18h, et le samedi de 8h à 18h à Champigny. Pour toute information, connaître ou rejoindre notre groupe, rendez-vous sur notre site : www.cmn-idf.fr Pour toute question sur un dossier patient ou une demande urgente, contactez-nous par mail (en précisant le Centre concerné) à : medecins@cmn-idf.fr

Groupe d’entreprises locales spécialisées dans la conception, la construction et la maintenance des réseaux de distribution des énergies, des télécommunications et de l’eau.

► About us: BCF Life Sciences specialises in the extraction of natural amino acids (L-Cystine and L-Tyrosine) and their derivatives (Carbocisteine, etc.) of 100 % traced origin for the pharmaceutical and health care industries. BCF Life Sciences products are marketed by the leading names in the fields of pharmaceuticals, food supplements (nutraceuticals) and baby foods. ► Innovative Free Amino Acids Mixes: BCF Life Sciences also develops and markets a range of highly soluble and highly bioavailable free amino acid mixes with very low molecular weight. Those free amino acid mixes are intended for industrial customers specialising in human nutrition (aromatic raw materials for culinary preparations), animal nutrition (nutrition & health for veterinary applications, attractants for aquaculture, for example) and plant nutrition (foliar biostimulants). ► Key Figures 38,2 million Euros in 2018 185 employees in 2020 64% of sales made overseas in 2020 2 sales offices based in Thailand and Colombia ► Our Values ◆ Placing the client at the center of all our actions ◆ Everyday enhancing quality by continuous development ◆ Placing the team before the individual: priority on cooperation ◆ Thinking "out of the box"​ : making the impossible possible ◆ Being an open company that is curious and openly talking about its habits

When a product formulated by a doctor and listed by pharmacies for over 65 years becomes the favorite of backstage. In 1950, a dermatologist from a Parisian hospital specialized in skin pathologies, created the Lait-Crème Concentré, which has become a myth. From this expertise was born a whole range of skin cares, then of make-up preparation, passed on from mothers to daughters, and from generation to generation. It has the unique particularity of being approved by dermatologists, just a well as chemists and make-up professionals.